NeuroSense Therapeutics Management
Management criteria checks 3/4
NeuroSense Therapeutics' CEO is Alon Ben-Noon, appointed in Jan 2016, has a tenure of 9.08 years. total yearly compensation is $1.01M, comprised of 36.2% salary and 63.8% bonuses, including company stock and options. directly owns 13.33% of the company’s shares, worth $3.54M. The average tenure of the management team and the board of directors is 3.1 years and 3.2 years respectively.
Key information
Alon Ben-Noon
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 36.2% |
| CEO tenure | 9.1yrs |
| CEO ownership | 13.3% |
| Management average tenure | 3.1yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely
Mar 22
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?
Dec 06Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Mar 03Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Nov 17NeuroSense Therapeutics GAAP EPS of -$0.55
Aug 31We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
Jul 06NeuroSense climbs 66% after early data supporting Alzheimer’s candidate
Jun 30Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?
Mar 31NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans
Mar 22NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases
Dec 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$12m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$13m |
| Dec 31 2023 | US$1m | US$367k | -US$10m |
| Sep 30 2023 | n/a | n/a | -US$11m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$2m | US$410k | -US$10m |
Compensation vs Market: Alon's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD637.96K).
Compensation vs Earnings: Alon's compensation has been consistent with company performance over the past year.
CEO
Alon Ben-Noon (45 yo)
9.1yrs
Tenure
US$1,013,000
Compensation
Mr. Alon Ben-Noon is the Co-Founder of NeuroSense Therapeutics Ltd. and serves as its Chief Executive Officer since 2016 and Director since February 2017. Mr. Ben-Noon served as Chair of Board of Directors...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.1yrs | US$1.01m | 13.33% $ 3.5m | |
| Chief Financial Officer | 3.7yrs | US$1.02m | 1.99% $ 529.0k | |
| Chief Operation Officer | no data | US$266.62k | 0.095% $ 25.3k | |
| Chief Technology Officer | 1.8yrs | US$291.62k | 0.28% $ 75.2k | |
| Chief Medical Officer | 3.2yrs | US$918.00k | 0.53% $ 141.4k | |
| VP of Quality & Compliance | 3.1yrs | no data | no data | |
| Head of HR | 1.7yrs | no data | no data | |
| C.R.A. | 2.1yrs | no data | no data |
3.1yrs
Average Tenure
45.5yo
Average Age
Experienced Management: NRSN's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8yrs | US$1.01m | 13.33% $ 3.5m | |
| Independent Chairman of the Board | 3.3yrs | US$1.48m | 0.28% $ 73.6k | |
| Independent External Director | 3.2yrs | US$104.00k | 0.10% $ 27.6k | |
| Independent External Director | 3.2yrs | US$104.00k | 0.10% $ 27.6k | |
| Chair of Scientific Advisory Board | no data | no data | no data | |
| Director | 3.1yrs | US$91.00k | 0.12% $ 32.8k | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data |
3.2yrs
Average Tenure
56yo
Average Age
Experienced Board: NRSN's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 10:23 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeuroSense Therapeutics Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Nazibur Rahman | Maxim Group |